TARA Protara Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why TARA matters now
Protara Therapeutics, Inc. (TARA) is a US stock in Healthcare. The latest InvestLog snapshot shows $4.32 with +2.86% on the session and $166.7M in market capitalization; recent performance reads 1-month -8.29% and YTD -25.33%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-17.8M, and EPS of $-0.42. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -41.0%.
The latest indexable market news headline is "Tradeweb Launches TARA, an AI-Powered Research Assistant for Institutional Credit Trading" from Business Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $12.00; recent insider activity includes BESHAR LUKE M filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.94
P/S
0.00
EV/EBITDA
-2.25
DCF Value
$1.03
FCF Yield
-41.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-38.7%
ROA
-33.0%
ROIC
-38.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-17.8M | $-0.42 |
| Q4 2025 | $0.00 | $-17.3M | $-0.38 |
| FY 2025 | $0.00 | $-57.4M | $-1.34 |
| Q3 2025 | $0.00 | $-13.3M | $-0.31 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$12.00
Target (Median)
$12.00
Target Range
$12.00 - $12.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.45
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.